Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results Meeting Abstract

  

Authors:	Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Nowfar, S.; Einstein, D. J.; Martin, B.; Adorjan, P.; Dissanayake, M.; Verholen, F.; Gao, X.
Abstract Title:	Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results
Meeting Title:	2025 ASCO Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	5 Suppl.
Meeting Dates:	2025 Feb 13-15
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-02-10
Language:	English
ACCESSION:	WOS:001454759900038
DOI:	10.1200/JCO.2025.43.5_suppl.150
PROVIDER:	wos
Notes:	Meeting Abstract: 150 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225290